Billionaires Stanley Druckenmiller and Ken Griffin Increase Stakes in Eli Lilly
In Q2 of 2026, billionaire investors Stanley Druckenmiller and Ken Griffin both increased their positions in Eli Lilly (NYSE: LLY), a major pharmaceutical company. Citadel Advisors, managed by Griffin, boosted its stake by 291%, making it the eighth-largest holding with an estimated value of $1.1 billion at quarter-end. Meanwhile, Druckenmiller's Duquesne Family Office initiated a new position in Lilly after exiting earlier in Q3 2025. Both investors likely recognized Eli Lilly’s strong market presence and recent performance driven by blockbuster drugs like Mounjaro and Zepbound, which are leading the company's revenue growth. The stock had previously dropped to as much as 23% below its high but has since recovered some ground with a solid year-to-date gain. Despite their purchases, analysts caution that investors should not follow suit solely based on these moves. However, Lilly’s continued strong earnings and pipeline of new drugs suggest it remains an attractive investment for those who conduct independent analysis.
